Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor
Cancer Immunology, Immunotherapy · 2023
DOI: 10.1007/s00262-023-03556-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Derrick McCarthy und 10 weiteren Autor:innen. Beteiligte Einrichtung: TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA. Hauptthemen laut MEDLINE: CD28 Antigens, Mesothelioma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
T cells expressing a mesothelin (MSLN)-specific T cell receptor fusion construct (TRuC ® ), called TC-210, have demonstrated robust antitumor activity in preclinical models of mesothelioma, ovarian cancer, and lung cancer. However, they are susceptible to suppression by the programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis and lack intrinsic costimulatory signaling elements. To enhance the function of anti-MSLN TRuC-T cells, chimeric switch receptors (CSRs) have been designed to co-opt the immunosuppressive PD-1/PD-L1 axis and to deliver a CD28-mediated costimulatory signal. Here, we report that coexpression of the PD1-CD28 CSR in TRuC-T cells enhanced T cell receptor signaling, increased proinflammatory effector cytokines, decreased anti-inflammatory cytokines, and sustained effector function in the presence of PD-L1 when compared with TC-210. Anti-MSLN TRuC-T cells engineered to coexpress PD1-CD28 CSRs comprising the ectodomain of PD-1 and the intracellular domain of CD28 linked by the transmembrane domain of PD-1 were selected for integration into an anti-MSLN TRuC-T cell therapy product called TC-510. In vitro, TC-510 showed significant improvements in persistence and resistance to exhaustion upon chronic stimulation by tumor cells expressing MSLN and PD-L1 when compared with TC-210. In vivo, TC-510 showed a superior ability to provide durable protection following tumor rechallenge, versus TC-210. These data demonstrate that integration of a PD1-CD28 CSR into TRuC-T cells improves effector function, resistance to exhaustion, and prolongs persistence. Based on these findings, TC-510 is currently being evaluated in patients with MSLN-expressing solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.
- Adaptimmune, Philadelphia, PA, USA.
- Center of Integrated Protein Science Munich (CIPS‑M) and Division of Clinical Pharmacology, Department of Medicine IV, Member of the German Center for Lung Research (DZL), University Hospital, Ludwig-Maximilians-Univers…
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
- Institute of Immunology, Ludwig-Maximilians-Universität, Munich, Germany.
- TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA. rob.tighe1973@gmail.com.
Zitieren
APA
McCarthy, D., Lofgren, M., Watt, A., Horton, H., Kieffer-Kwon, P., Ding, J., Kobold, S., Baeuerle, P. A., Hofmeister, R., Gutierrez, D. A., & Tighe, R. (2023). Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03556-7
Vancouver
McCarthy D, Lofgren M, Watt A, Horton H, Kieffer-Kwon P, Ding J, et al. Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03556-7
BibTeX
@article{McCarthy2023,
author = {McCarthy, Derrick and Lofgren, Michael and Watt, Amy and Horton, Holly and Kieffer-Kwon, Philippe and Ding, Jian and Kobold, Sebastian and Baeuerle, Patrick A and Hofmeister, Robert and Gutierrez, Dario A and Tighe, Robert},
title = {Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
doi = {10.1007/s00262-023-03556-7}
}
EUVIMED